STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with the Company’s pending merger with Alcon (SIX/NYSE: ALC). STAAR will hold a Special Meeting of Stockholders on October 23 at 8:30 a.m. (Pacific Time) to vote to adopt the